CTOs on the Move

Renalytix

www.renalytix.com

 
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company`s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.renalytix.com
  • 101 Avenue of the Americas Suite 324
    New York, NY USA 10013
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Cytokine PharmaSciences

Cytokine PharmaSciences is a King Of Prussia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allied Safety Associates

Allied Safety Associates is a West Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HomeDNA

HomeDNA, Inc. is a Keller, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adaptive Phage

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT`s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT`s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

Senseonics

Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.